These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
265 related articles for article (PubMed ID: 34818060)
1. Small-molecule antagonism of the interaction of the RAGE cytoplasmic domain with DIAPH1 reduces diabetic complications in mice. Manigrasso MB; Rabbani P; Egaña-Gorroño L; Quadri N; Frye L; Zhou B; Reverdatto S; Ramirez LS; Dansereau S; Pan J; Li H; D'Agati VD; Ramasamy R; DeVita RJ; Shekhtman A; Schmidt AM Sci Transl Med; 2021 Nov; 13(621):eabf7084. PubMed ID: 34818060 [TBL] [Abstract][Full Text] [Related]
2. Deletion of the formin Diaph1 protects from structural and functional abnormalities in the murine diabetic kidney. Manigrasso MB; Friedman RA; Ramasamy R; D'Agati V; Schmidt AM Am J Physiol Renal Physiol; 2018 Dec; 315(6):F1601-F1612. PubMed ID: 30132346 [TBL] [Abstract][Full Text] [Related]
3. The RAGE/DIAPH1 Signaling Axis & Implications for the Pathogenesis of Diabetic Complications. Ramasamy R; Shekhtman A; Schmidt AM Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562970 [TBL] [Abstract][Full Text] [Related]
4. RAGE/DIAPH1 and atherosclerosis through an evolving lens: Viewing the cell from the "Inside - Out". Ramasamy R; Shekhtman A; Schmidt AM Atherosclerosis; 2024 Jul; 394():. PubMed ID: 39131441 [TBL] [Abstract][Full Text] [Related]
5. The cross-talk between RAGE and DIAPH1 in neurological complications of diabetes: A review. Zglejc-Waszak K; Mukherjee K; Juranek JK Eur J Neurosci; 2021 Sep; 54(6):5982-5999. PubMed ID: 34449932 [TBL] [Abstract][Full Text] [Related]
7. Small Molecule Inhibition of Ligand-Stimulated RAGE-DIAPH1 Signal Transduction. Manigrasso MB; Pan J; Rai V; Zhang J; Reverdatto S; Quadri N; DeVita RJ; Ramasamy R; Shekhtman A; Schmidt AM Sci Rep; 2016 Mar; 6():22450. PubMed ID: 26936329 [TBL] [Abstract][Full Text] [Related]
8. The RAGE/DIAPH1 axis: mediator of obesity and proposed biomarker of human cardiometabolic disease. Arivazhagan L; Popp CJ; Ruiz HH; Wilson RA; Manigrasso MB; Shekhtman A; Ramasamy R; Sevick MA; Schmidt AM Cardiovasc Res; 2024 Feb; 119(18):2813-2824. PubMed ID: 36448548 [TBL] [Abstract][Full Text] [Related]
9. Novel insights into the nervous system affected by prolonged hyperglycemia. Zglejc-Waszak K; Mukherjee K; Korytko A; Lewczuk B; Pomianowski A; Wojtkiewicz J; Banach M; Załęcki M; Nowicka N; Jarosławska J; Kordas B; Wąsowicz K; Juranek JK J Mol Med (Berl); 2023 Aug; 101(8):1015-1028. PubMed ID: 37462767 [TBL] [Abstract][Full Text] [Related]
10. Signal transduction in receptor for advanced glycation end products (RAGE): solution structure of C-terminal rage (ctRAGE) and its binding to mDia1. Rai V; Maldonado AY; Burz DS; Reverdatto S; Yan SF; Schmidt AM; Shekhtman A J Biol Chem; 2012 Feb; 287(7):5133-44. PubMed ID: 22194616 [TBL] [Abstract][Full Text] [Related]
11. Glycation & the RAGE axis: targeting signal transduction through DIAPH1. Shekhtman A; Ramasamy R; Schmidt AM Expert Rev Proteomics; 2017 Feb; 14(2):147-156. PubMed ID: 27967251 [TBL] [Abstract][Full Text] [Related]
12. Receptor for Advanced Glycation End Products (RAGE) and Mechanisms and Therapeutic Opportunities in Diabetes and Cardiovascular Disease: Insights From Human Subjects and Animal Models. Egaña-Gorroño L; López-Díez R; Yepuri G; Ramirez LS; Reverdatto S; Gugger PF; Shekhtman A; Ramasamy R; Schmidt AM Front Cardiovasc Med; 2020; 7():37. PubMed ID: 32211423 [TBL] [Abstract][Full Text] [Related]
13. Mammalian Diaphanous1 signalling in neurovascular complications of diabetes. Jarosławska J; Kordas B; Miłowski T; Juranek JK Eur J Neurosci; 2024 May; 59(10):2628-2645. PubMed ID: 38491850 [TBL] [Abstract][Full Text] [Related]
14. The Receptor for Advanced Glycation End Products (RAGE) and DIAPH1: Implications for vascular and neuroinflammatory dysfunction in disorders of the central nervous system. MacLean M; Derk J; Ruiz HH; Juranek JK; Ramasamy R; Schmidt AM Neurochem Int; 2019 Jun; 126():154-164. PubMed ID: 30902646 [TBL] [Abstract][Full Text] [Related]
15. Diaphanous-1 affects the nanoscale clustering and lateral diffusion of receptor for advanced glycation endproducts (RAGE). Zhu Q; Smith EA Biochim Biophys Acta Biomembr; 2019 Jan; 1861(1):43-49. PubMed ID: 30401627 [TBL] [Abstract][Full Text] [Related]
16. The multiple faces of RAGE--opportunities for therapeutic intervention in aging and chronic disease. Ramasamy R; Shekhtman A; Schmidt AM Expert Opin Ther Targets; 2016; 20(4):431-46. PubMed ID: 26558318 [TBL] [Abstract][Full Text] [Related]
18. 22016 ATVB Plenary Lecture: Receptor for Advanced Glycation Endproducts and Implications for the Pathogenesis and Treatment of Cardiometabolic Disorders: Spotlight on the Macrophage. Schmidt AM Arterioscler Thromb Vasc Biol; 2017 Apr; 37(4):613-621. PubMed ID: 28183700 [TBL] [Abstract][Full Text] [Related]
19. The receptor for advanced glycation end products and its ligands' expression in OVE26 diabetic sciatic nerve during the development of length-dependent neuropathy. Zglejc-Waszak K; Schmidt AM; Juranek JK Neuropathology; 2023 Feb; 43(1):84-94. PubMed ID: 35915909 [TBL] [Abstract][Full Text] [Related]
20. New insights into RAGE/Diaph1 interaction as a modulator of actin cytoskeleton dynamics in peripheral nervous system in long-term hyperglycaemia. Zglejc-Waszak K; Pomianowski A; Wojtkiewicz J; Banach M; Juranek JK Eur J Neurosci; 2023 May; 57(10):1642-1656. PubMed ID: 37070486 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]